IL150698A0 - Processes for preparing clarithromycin polymorphs - Google Patents

Processes for preparing clarithromycin polymorphs

Info

Publication number: IL150698A0
Authority: IL; Israel
Prior art keywords: processes; clarithromycin; preparing clarithromycin; polymorphs; converting
Prior art date: 2000-01-11

Application number

IL15069800A

Other languages

English (en)

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-11

Filing date

2000-12-15

Publication date

2003-02-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22640371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL150698(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-12-15 Application filed by Teva Pharma filed Critical Teva Pharma

2003-02-12 Publication of IL150698A0 publication Critical patent/IL150698A0/xx

Links

AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 title abstract 8
229960002626 clarithromycin Drugs 0.000 title abstract 3
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 abstract 1
229930006677 Erythromycin A Natural products 0.000 abstract 1
229960003276 erythromycin Drugs 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

IL15069800A 2000-01-11 2000-12-15 Processes for preparing clarithromycin polymorphs IL150698A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17547700P	2000-01-11	2000-01-11
PCT/US2000/033844 WO2001051059A1 (en)	2000-01-11	2000-12-15	Processes for preparing clarithromycin polymorphs

Publications (1)

Publication Number	Publication Date
IL150698A0 true IL150698A0 (en)	2003-02-12

Family

ID=22640371

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL15069800A IL150698A0 (en)	2000-01-11	2000-12-15	Processes for preparing clarithromycin polymorphs

Country Status (22)

Country	Link
US (2)	US6624292B2 (de)
EP (1)	EP1280535B1 (de)
JP (1)	JP2003519661A (de)
KR (1)	KR20020071012A (de)
CN (1)	CN1450903A (de)
AT (1)	ATE288758T1 (de)
AU (2)	AU2001222619C1 (de)
BR (1)	BR0016992A (de)
CA (1)	CA2397092A1 (de)
DE (1)	DE60018119T2 (de)
DK (1)	DK1280535T3 (de)
ES (1)	ES2236023T3 (de)
HR (1)	HRP20020572A2 (de)
HU (1)	HUP0204252A3 (de)
IL (1)	IL150698A0 (de)
IS (1)	IS6463A (de)
PL (1)	PL356645A1 (de)
PT (1)	PT1280535E (de)
RU (1)	RU2002118308A (de)
SI (1)	SI1280535T1 (de)
WO (1)	WO2001051059A1 (de)
ZA (1)	ZA200205229B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ20021999A3 (cs) *	1999-12-16	2003-02-12	Teva Pharmaceutical Industries Ltd.	Způsob přípravy klaritromycinových polymorfních forem a nového polymorfu IV
CA2397092A1 (en) *	2000-01-11	2001-07-19	Teva Pharmaceutical Industries Ltd.	Processes for preparing clarithromycin polymorphs
US6544555B2 (en) *	2000-02-24	2003-04-08	Advancis Pharmaceutical Corp.	Antibiotic product, use and formulation thereof
US6565882B2 (en)	2000-02-24	2003-05-20	Advancis Pharmaceutical Corp	Antibiotic composition with inhibitor
WO2001064224A1 (en) *	2000-02-29	2001-09-07	Teva Pharmaceutical Industries Ltd.	Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
ATE432691T1 (de) *	2000-03-28	2009-06-15	Sandoz Ag	Geschmackmaskierte granulierte teilchen
US20020068078A1 (en) *	2000-10-13	2002-06-06	Rudnic Edward M.	Antifungal product, use and formulation thereof
US6541014B2 (en)	2000-10-13	2003-04-01	Advancis Pharmaceutical Corp.	Antiviral product, use and formulation thereof
ES2288898T3 (es) *	2001-08-13	2008-02-01	Fondazione Salvatore Maugeri - Clinica del Lavoro e della Riabilitazione	Uso de composiciones de claritromicina en la fabricacion de un medicamento para el tratamiento de la artritis deformante.
US20060083759A1 (en) *	2002-07-17	2006-04-20	Aleksander Resman	Stabilization of the profile of release of active substances from a formulation
CA2533178C (en)	2003-07-21	2014-03-11	Advancis Pharmaceutical Corporation	Antibiotic product, use and formulation thereof
JP2006528190A (ja)	2003-07-21	2006-12-14	アドバンシスファーマスーティカルコーポレイション	抗生物質製剤、その使用法及び作成方法
JP2006528185A (ja)	2003-07-21	2006-12-14	アドバンシスファーマスーティカルコーポレイション	抗生物質製剤、その使用法及び作成方法
WO2005016311A1 (en)	2003-08-11	2005-02-24	Advancis Pharmaceutical Corporation	Robust pellet
AU2004264356B2 (en)	2003-08-12	2011-01-27	Shionogi, Inc.	Antibiotic product, use and formulation thereof
JP5686494B2 (ja) *	2003-08-29	2015-03-18	シオノギインコーポレイテッド	抗生物質製剤、その使用法及び作成方法
EP1663169A4 (de)	2003-09-15	2010-11-24	Middlebrook Pharmaceuticals In	Antibiotisches produkt, seine verwendung und formulierung
WO2005061524A2 (en) *	2003-12-22	2005-07-07	Ranbaxy Laboratories Limited	Process for the preparation of form ii clarithromycin
CA2550983C (en) *	2003-12-24	2013-09-17	Advancis Pharmaceutical Corporation	Enhanced absorption of modified release dosage forms
JP4833862B2 (ja) *	2004-01-28	2011-12-07	サイトイミューンサイエンシズインコーポレイテッド	官能化コロイド金属組成物および方法
US7468428B2 (en) *	2004-03-17	2008-12-23	App Pharmaceuticals, Llc	Lyophilized azithromycin formulation
US20060116336A1 (en) *	2004-03-17	2006-06-01	American Pharmaceutical Partners, Inc.	Lyophilized azithromycin formulation
WO2006014427A1 (en)	2004-07-02	2006-02-09	Advancis Pharmaceutical Corporation	Tablet for pulsed delivery
WO2007008537A2 (en) *	2005-07-07	2007-01-18	Elan Pharma International, Limited	Nanoparticulate clarithromycin formulations
US20070122483A1 (en) *	2005-11-29	2007-05-31	Sharon Myers	Fluocinolone acetonide drug substance polymorphic interconversion
US8778924B2 (en)	2006-12-04	2014-07-15	Shionogi Inc.	Modified release amoxicillin products
US8357394B2 (en)	2005-12-08	2013-01-22	Shionogi Inc.	Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en)	2006-05-05	2012-10-30	Shionogi Inc.	Pharmaceutical compositions and methods for improved bacterial eradication
WO2011026234A1 (en) *	2009-09-02	2011-03-10	Bernard Charles Sherman	Clarithromycin extended-release tablet
TWI665190B (zh)	2013-11-15	2019-07-11	阿克比治療有限公司	｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2473525A1 (fr)	1980-01-11	1981-07-17	Roussel Uclaf	Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments
US4331803A (en)	1980-06-04	1982-05-25	Taisho Pharmaceutical Co., Ltd.	Novel erythromycin compounds
JPS60214796A (ja)	1984-04-06	1985-10-28	Taisho Pharmaceut Co Ltd	６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja)	1984-10-26	1986-05-22	Taisho Pharmaceut Co Ltd	６−０−メチルエリスロマイシンａ誘導体
US4670549A (en)	1985-03-18	1987-06-02	Taisho Pharmaceutical Co., Ltd.	Method for selective methylation of erythromycin a derivatives
US4640910A (en)	1985-11-12	1987-02-03	Abbott Laboratories	Erythromycin A silylated compounds and method of use
US4672056A (en)	1985-11-12	1987-06-09	Abbott Laboratories	Erythromycin A derivatives and method of use
KR960000434B1 (ko)	1986-12-17	1996-01-06	다이쇼 세이야꾸 가부시끼가이샤	에리스로마이신 a유도체 및 그의 제조 방법
GB8721165D0 (en)	1987-09-09	1987-10-14	Beecham Group Plc	Chemical compounds
JP2751385B2 (ja)	1988-05-19	1998-05-18	大正製薬株式会社	エリスロマイシンａオキシム及びその塩の製造方法
US5440505A (en) *	1994-01-21	1995-08-08	Intel Corporation	Method and circuitry for storing discrete amounts of charge in a single memory element
US5872229A (en)	1995-11-21	1999-02-16	Abbott Laboratories	Process for 6-O-alkylation of erythromycin derivatives
US5756473A (en)	1995-11-21	1998-05-26	Abbott Laboratories	6-O-methyl erythromycin D and process for making
US5837829A (en)	1996-04-02	1998-11-17	Abbott Laboratories	9-oximesilyl erythromycin a derivatives
US5719272A (en)	1996-04-02	1998-02-17	Abbott Laboratories	2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5808017A (en)	1996-04-10	1998-09-15	Abbott Laboratories	Process for preparing erythromycin A oxime
US5844105A (en)	1996-07-29	1998-12-01	Abbott Laboratories	Preparation of crystal form II of clarithromycin
PT915899E (pt)	1996-07-29	2004-11-30	Abbott Lab	Preparacao da forma cristalina ii da eritromicina
US5858986A (en)	1996-07-29	1999-01-12	Abbott Laboratories	Crystal form I of clarithromycin
US5945405A (en)	1997-01-17	1999-08-31	Abbott Laboratories	Crystal form O of clarithromycin
US5864023A (en)	1997-02-13	1999-01-26	Abbott Laboratories	3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
US5852180A (en)	1997-11-17	1998-12-22	Abbott Laboratories	Chemical synthesis of 6-O-alkyl erythromycin A
US5932710A (en)	1997-12-01	1999-08-03	Abbott Laboratories	Process for preparing 6-O-alkyl-9-oxime erythromycin B
US5892008A (en)	1997-12-16	1999-04-06	Abbott Laboratories	Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives
KR100377159B1 (ko)	1998-09-09	2003-08-19	한미약품공업 주식회사	잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
CZ20021999A3 (cs) *	1999-12-16	2003-02-12	Teva Pharmaceutical Industries Ltd.	Způsob přípravy klaritromycinových polymorfních forem a nového polymorfu IV
CA2397092A1 (en) *	2000-01-11	2001-07-19	Teva Pharmaceutical Industries Ltd.	Processes for preparing clarithromycin polymorphs
WO2001064224A1 (en) *	2000-02-29	2001-09-07	Teva Pharmaceutical Industries Ltd.	Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same

2000
- 2000-12-15 CA CA002397092A patent/CA2397092A1/en not_active Abandoned
- 2000-12-15 AU AU2001222619A patent/AU2001222619C1/en not_active Ceased
- 2000-12-15 SI SI200030650T patent/SI1280535T1/xx unknown
- 2000-12-15 AU AU2261901A patent/AU2261901A/xx active Pending
- 2000-12-15 EP EP00986367A patent/EP1280535B1/de not_active Revoked
- 2000-12-15 BR BR0016992-7A patent/BR0016992A/pt not_active Application Discontinuation
- 2000-12-15 RU RU2002118308/15A patent/RU2002118308A/ru unknown
- 2000-12-15 PL PL00356645A patent/PL356645A1/xx not_active Application Discontinuation
- 2000-12-15 US US09/736,446 patent/US6624292B2/en not_active Expired - Fee Related
- 2000-12-15 PT PT00986367T patent/PT1280535E/pt unknown
- 2000-12-15 DE DE60018119T patent/DE60018119T2/de not_active Expired - Fee Related
- 2000-12-15 ES ES00986367T patent/ES2236023T3/es not_active Expired - Lifetime
- 2000-12-15 IL IL15069800A patent/IL150698A0/xx unknown
- 2000-12-15 KR KR1020027008908A patent/KR20020071012A/ko not_active Ceased
- 2000-12-15 AT AT00986367T patent/ATE288758T1/de not_active IP Right Cessation
- 2000-12-15 WO PCT/US2000/033844 patent/WO2001051059A1/en not_active Ceased
- 2000-12-15 DK DK00986367T patent/DK1280535T3/da active
- 2000-12-15 HR HR20020572A patent/HRP20020572A2/hr not_active Application Discontinuation
- 2000-12-15 CN CN00819302A patent/CN1450903A/zh active Pending
- 2000-12-15 JP JP2001551483A patent/JP2003519661A/ja not_active Withdrawn
- 2000-12-15 HU HU0204252A patent/HUP0204252A3/hu unknown
2002
- 2002-06-28 ZA ZA200205229A patent/ZA200205229B/en unknown
- 2002-07-09 IS IS6463A patent/IS6463A/is unknown
2003
- 2003-06-10 US US10/459,178 patent/US6987175B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
RU2002118308A (ru)	2004-02-20
ES2236023T3 (es)	2005-07-16
HRP20020572A2 (en)	2005-04-30
DE60018119T2 (de)	2006-05-04
DK1280535T3 (da)	2005-04-04
US6987175B2 (en)	2006-01-17
EP1280535B1 (de)	2005-02-09
DE60018119D1 (de)	2005-03-17
EP1280535A1 (de)	2003-02-05
HUP0204252A2 (hu)	2003-03-28
IS6463A (is)	2002-07-09
AU2261901A (en)	2001-07-24
HUP0204252A3 (en)	2003-04-28
ZA200205229B (en)	2003-06-30
CA2397092A1 (en)	2001-07-19
US20030216555A1 (en)	2003-11-20
US6624292B2 (en)	2003-09-23
AU2001222619B2 (en)	2005-04-28
PT1280535E (pt)	2005-04-29
EP1280535A4 (de)	2003-02-05
CN1450903A (zh)	2003-10-22
AU2001222619C1 (en)	2006-01-12
ATE288758T1 (de)	2005-02-15
KR20020071012A (ko)	2002-09-11
BR0016992A (pt)	2002-12-31
WO2001051059A1 (en)	2001-07-19
US20020028920A1 (en)	2002-03-07
SI1280535T1 (de)	2005-08-31
JP2003519661A (ja)	2003-06-24
AU2001222619B8 (en)	2005-07-14
PL356645A1 (en)	2004-06-28

Publication	Publication Date	Title
AU2261901A (en)	2001-07-24	Processes for preparing clarithromycin polymorphs
MXPA03005222A (es)	2004-03-26	Derivado de metanosulfonamido-benzofurano, su procedimiento de preparacion y su utilizacion como intermediario de sisntesis.
ZA200206253B (en)	2003-07-02	Oxygenate conversion process.
MXPA03005028A (es)	2004-01-29	Derivados de cetolida de 6-0-carbamoilo de eritromicina, utiles como antibacterianos.
IL150227A0 (en)	2002-12-01	Processes for preparing clarithromycin polymorphs and novel polymorph iv
ZA200200609B (en)	2003-03-26	Process for producing phenyl-alkanes compositions produced thereform, and uses thereof.
MXPA03001590A (es)	2003-06-04	Anticuerpos para la il-1beta humana.
EG24742A (en)	2010-07-14	Vaccine composition.
YU27403A (sh)	2006-03-03	Postupak za pripremanje preparata u obliku praha
AU2001222619A1 (en)	2001-10-04	Processes for preparing clarithromycin polymorphs
ZA200309471B (en)	2004-12-06	Method for the preparation of escitalopram.
ZA200102070B (en)	2002-09-13	Process for preparing resorcinol derivatives.
HUP0301108A3 (en)	2008-04-28	Oxidation process for preparing the intermediate 6alpha, 9alpha
ZA200403432B (en)	2005-05-06	Method for the preparation of escitalopram.
GB2369369B (en)	2004-08-18	Process for converting synthesis gas
MXPA03002464A (es)	2003-06-19	Proceso para preparar benzotriazoles.
MXPA01012693A (es)	2003-08-20	Produccion mejorada de tequila.
MXPA03002926A (es)	2003-08-07	Proceso para la sintesis de 2,2,6,6,-tetrametil-4--oxipiperidina.
YU53302A (sh)	2005-06-10	Postupci za pripremanje polimorfa klaritromicina
ZA200106159B (en)	2002-02-07	Method for production of catalyst.
AU6898101A (en)	2001-12-03	Method for producing 2-chloro-5-chloromethyl-1,3-thiazole
ES2197790A1 (es)	2004-01-01	Compuesto intermedio de utilidad en la sintesis de macrolidos.
IL152295A0 (en)	2003-05-29	Method for producing 2-alkyl-3-chlorophenols
MXPA03000664A (es)	2003-06-06	Derivados n-sustituidos del acido 1-amino-1, 1-dialquilcarboxilico.
MY133929A (en)	2007-11-30	A cost effective method for selective methylation of erythromycin a derivatives